Cue Biopharma raises $50.0 million in private placement
Cue Biopharma, Inc. has secured $50.0 million via a private placement led by Cormorant Asset Management and Columbia Threadneedle Investments. The transaction involves the sale of 1,418,071 shares at $33.21 per share and pre-funded warrants for 87,500 shares. The offering is expected to close on July 13, 2026, with proceeds allocated for clinical development and general corporate purposes. The company also agreed to file a registration statement for the resale of these securities.
*this image is generated using AI for illustrative purposes only.
Cue Biopharma, Inc. has secured approximately $50.0 million in gross proceeds through a private placement led by Cormorant Asset Management, with participation from Columbia Threadneedle Investments. The clinical-stage biopharmaceutical company entered into a securities purchase agreement to sell 1,418,071 shares of common stock at a purchase price of $33.21 per share. Additionally, certain investors received pre-funded warrants to purchase up to 87,500 shares of common stock at a price of $33.209 per pre-funded warrant in lieu of common stock.
The private placement is expected to close on or about July 13, 2026, subject to customary closing conditions. The pre-funded warrants will be immediately exercisable at an exercise price of $0.001 per share and will remain exercisable until exercised in full. Cue Biopharma intends to use the net proceeds from this offering to further fund clinical development and for other general corporate purposes.
Key Terms of the Private Placement
The following table outlines the primary components of the securities issued:
| Component | Details |
|---|---|
| Common Stock Shares | 1,418,071 |
| Purchase Price per Share | $33.21 |
| Pre-Funded Warrants (Shares) | 87,500 |
| Price per Pre-Funded Warrant | $33.209 |
| Warrant Exercise Price | $0.001 per share |
| Gross Proceeds | ~$50.0 million |
Strategic Use of Proceeds
Shao-Lee Lin, M.D., Ph.D., chief executive officer, president and board director of Cue Biopharma, emphasized the significance of the investment. "We are pleased to have such a high-quality group of biotech investors committing to the long-term support of Cue as we build our company and advance our portfolio targeting functional cures across immunological disorders," said Lin. The company is anticipating upcoming clinical milestones, including data from Ascendant Health’s ongoing Phase 2 CSU study in China, expected by the end of the third quarter of 2026.
Regulatory and Registration Details
The securities issued, including the shares of common stock underlying the pre-funded warrants, have not been registered under the Securities Act of 1933, as amended. Consequently, these securities may not be offered or sold in the United States absent an effective registration statement or an applicable exemption. Concurrently with the purchase agreement, the company and investors entered into a registration rights agreement. Cue Biopharma has agreed to file a registration statement with the Securities and Exchange Commission to register the resale of the shares sold in the private placement and the shares underlying the pre-funded warrants.
How will the $50 million in proceeds specifically impact the timeline for upcoming clinical milestones?
What potential market reactions should investors expect following the release of Phase 2 CSU study data in late 2026?
Could this private placement signal further strategic partnerships or collaborations for Cue Biopharma?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
